fda bpc-157 warning unapproved FDA's Overreach on Compounded Peptides fda warning unapproved peptides bpc-157
Description
"Pharmaceutical companies will say there are drugs which appear to have potential but never go on beyond an early development phase, so this means the whole process of interpreting data and how things can be categorised under the WADA list is difficult and subject to interpretation." - with Jon Ralph
How do you know if your tirzepatide dose is too high
EscudierBPowlesTMotzerRJOlenckiTArn FronteraOOudardSet al
This pattern is not unique to NAD+, as other nutrients or supplements have experienced similar cycles of hype, backlash, and eventual clarification through further, more rigorous research
Retatrutide's Phase 2a in MASH/MASLD (Sanyal et al., Nat Med 2024) reported approximately 86% relative reduction in liver fat content at 12 mg/week the strongest hepatic-fat data among the incretin class
Protocol Overview Concise summary of the oncedaily nightly regimen
